Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202603079 Effects of Different Treatment Strategies on the Incidence of Urinary Tract Infection in Patients with Asymptomatic Bacteriuria During the Acute to Subacute Phase After Stroke: A Double-Blind Randomized Controlled Trial New Drug Phase Ⅱ
N202603097 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1) New Drug Phase Ⅲ
N202603098 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2) New Drug Phase Ⅲ
N202603099 An open-label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301 New Drug Phase Ⅱ
N202603124 Dostarlimab, cisplatin and etoposide in combination with radiotherapy in sandwich sequence for small cell neuroendocrine cervical carcinoma （DICER trial）: Taiwanese Gynecologic Oncology Group (TGOG) 1012 New Drug Phase Ⅱ
N202603151 A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction New Drug Phase Ⅲ
N202603152 A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) versus Adjuvant Placebo Plus MK-3475A in Participants with Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013) New Drug Phase Ⅲ
N202603153 A Phase 1, open-label, dose-escalation study (ELEVATE-1) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven autoimmune rheumatic diseases (ARD) New Drug Phase Ⅰ
N202603154 Feasibility, toxicity, and biological effect of bortzomib with chemotherapy in patients with malignant rhabdoid tumors New Drug Academic Research / Phase Ⅲ
1 2 19 20 21 22 23 24 25 31 32 / 32

TOP